Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

<p>Abstract</p> <p>Background</p> <p>Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory the...

Full description

Bibliographic Details
Main Authors: Popp Felix C, Fillenberg Barbara, Eggenhofer Elke, Renner Philipp, Dillmann Johannes, Benseler Volker, Schnitzbauer Andreas A, Hutchinson James, Deans Robert, Ladenheim Deborah, Graveen Cheryl A, Zeman Florian, Koller Michael, Hoogduijn Martin J, Geissler Edward K, Schlitt Hans J, Dahlke Marc H
Format: Article
Language:English
Published: BMC 2011-07-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/9/1/124

Internet

http://www.translational-medicine.com/content/9/1/124

Similar Items